Hims & Hers Health, Inc. (NYSE:HIMS) Shares Purchased by Zurcher Kantonalbank Zurich Cantonalbank

Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 5.6% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 29,335 shares of the company’s stock after acquiring an additional 1,561 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Hims & Hers Health were worth $261,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in HIMS. FNY Investment Advisers LLC purchased a new stake in shares of Hims & Hers Health during the fourth quarter worth approximately $48,000. Belpointe Asset Management LLC acquired a new position in Hims & Hers Health in the 3rd quarter valued at $76,000. EMC Capital Management increased its stake in Hims & Hers Health by 80.0% in the 3rd quarter. EMC Capital Management now owns 12,000 shares of the company’s stock valued at $79,000 after buying an additional 5,332 shares during the period. Corton Capital Inc. purchased a new position in Hims & Hers Health during the 3rd quarter worth $122,000. Finally, Custom Index Systems LLC acquired a new stake in shares of Hims & Hers Health in the 4th quarter worth $132,000. 63.52% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, insider Soleil Boughton sold 4,080 shares of the firm’s stock in a transaction that occurred on Friday, February 9th. The shares were sold at an average price of $10.03, for a total transaction of $40,922.40. Following the sale, the insider now owns 154,345 shares in the company, valued at $1,548,080.35. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other Hims & Hers Health news, CEO Andrew Dudum sold 188,888 shares of Hims & Hers Health stock in a transaction dated Thursday, April 4th. The stock was sold at an average price of $14.97, for a total value of $2,827,653.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Soleil Boughton sold 4,080 shares of the stock in a transaction dated Friday, February 9th. The stock was sold at an average price of $10.03, for a total transaction of $40,922.40. Following the transaction, the insider now owns 154,345 shares in the company, valued at $1,548,080.35. The disclosure for this sale can be found here. Insiders sold a total of 736,191 shares of company stock valued at $9,733,700 over the last 90 days. Insiders own 31.63% of the company’s stock.

Hims & Hers Health Stock Performance

Hims & Hers Health stock opened at $11.26 on Monday. Hims & Hers Health, Inc. has a fifty-two week low of $5.65 and a fifty-two week high of $17.16. The stock has a fifty day moving average of $14.01 and a two-hundred day moving average of $10.31. The company has a market capitalization of $2.41 billion, a price-to-earnings ratio of -102.36 and a beta of 0.97.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings data on Monday, February 26th. The company reported $0.01 EPS for the quarter, topping analysts’ consensus estimates of ($0.02) by $0.03. The firm had revenue of $246.60 million during the quarter, compared to analysts’ expectations of $245.84 million. Hims & Hers Health had a negative return on equity of 7.21% and a negative net margin of 2.70%. The firm’s quarterly revenue was up 47.4% compared to the same quarter last year. During the same quarter last year, the business posted ($0.05) EPS. On average, analysts forecast that Hims & Hers Health, Inc. will post 0.11 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the stock. Canaccord Genuity Group assumed coverage on shares of Hims & Hers Health in a research note on Wednesday, April 10th. They set a “buy” rating and a $20.00 price target on the stock. Guggenheim boosted their target price on Hims & Hers Health from $15.00 to $17.00 and gave the stock a “buy” rating in a research report on Tuesday, February 27th. Citigroup raised their price target on Hims & Hers Health from $12.00 to $16.00 and gave the company a “buy” rating in a report on Tuesday, February 27th. Leerink Partnrs reaffirmed a “market perform” rating on shares of Hims & Hers Health in a report on Monday, February 26th. Finally, Seaport Res Ptn reiterated a “buy” rating on shares of Hims & Hers Health in a research report on Friday, April 26th. Five equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $14.85.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.